BIOMAT Database Logo BIOMAT Database Logo

Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. 1994

L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-alpha (TNF-alpha) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-alpha to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D005732 Gangliosides A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997) Ganglioside,Sialoglycosphingolipids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
July 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
August 1997, Melanoma research,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
May 1995, Cancer,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
February 1985, Proceedings of the National Academy of Sciences of the United States of America,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
February 2005, Cancer immunity,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Trafficking of ganglioside GD3 to mitochondria by tumor necrosis factor-alpha.
September 2002, The Journal of biological chemistry,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.
December 1992, Melanoma research,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.
February 2004, Cancer immunology, immunotherapy : CII,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
October 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L M Minasian, and T P Szatrowski, and M Rosenblum, and T Steffens, and M E Morrison, and P B Chapman, and L Williams, and C F Nathan, and A N Houghton
Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.
February 1984, Cancer research,
Copied contents to your clipboard!